secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2024-10-11T23:59:59+00:00
Accession:  0001558370-24-013246
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path raises ~$4M in private placement; launches obesity drug program BP1001-A
--------------------------------------------------------------------------------

- Gross proceeds of ~$4.0M from private placement of pre-funded warrants and series A/B warrants at $0.87 per unit; warrants exercisable at $1.00 per share.
- Initiated development of BP1001-A for obesity using DNAbilize technology; IND-enabling testing expected to begin in Q4 2024.
- Completed enrollment of third dosing cohort (60 mg/m2) of Phase 1/1b trial of BP1002 in refractory/relapsed AML patients.
- Cancelled prior June 2024 series A and B warrants (1,809,955 shares each) held by the same investor upon closing of this placement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024013246/0001558370-24-013246-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024013246/bpth-20241008x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-013246

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer